Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Details
Serval ID
serval:BIB_7EACCBC2761B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Journal
AIDS
Working group(s)
Efavirenz, Obesity Project Team on behalf of Collaboration of Observational H. I. V. Epidemiological Research Europe in EuroCoord
ISSN
1473-5571 (Electronic)
ISSN-L
0269-9370
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
29
Number
2
Pages
193-200
Language
english
Notes
Marzolini, Catia
Sabin, Caroline
Raffi, Francois
Siccardi, Marco
Mussini, Cristina
Launay, Odile
Burger, David
Roca, Bernardino
Fehr, Jan
Bonora, Stefano
Mocroft, Amanda
Obel, Niels
Dauchy, Frederic-Antoine
Zangerle, Robert
Gogos, Charalambos
Gianotti, Nicola
Ammassari, Adriana
Torti, Carlo
Ghosn, Jade
Chene, Genevieve
Grarup, Jesper
Battegay, Manuel
(COHERE)
eng
Observational Study
Research Support, Non-U.S. Gov't
England
AIDS. 2015 Jan 14;29(2):193-200. doi: 10.1097/QAD.0000000000000530.
Sabin, Caroline
Raffi, Francois
Siccardi, Marco
Mussini, Cristina
Launay, Odile
Burger, David
Roca, Bernardino
Fehr, Jan
Bonora, Stefano
Mocroft, Amanda
Obel, Niels
Dauchy, Frederic-Antoine
Zangerle, Robert
Gogos, Charalambos
Gianotti, Nicola
Ammassari, Adriana
Torti, Carlo
Ghosn, Jade
Chene, Genevieve
Grarup, Jesper
Battegay, Manuel
(COHERE)
eng
Observational Study
Research Support, Non-U.S. Gov't
England
AIDS. 2015 Jan 14;29(2):193-200. doi: 10.1097/QAD.0000000000000530.
Abstract
OBJECTIVE: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. DESIGN: Observational European cohort collaboration study. METHODS: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load (<50 copies/ml) after treatment initiation, and time to viral load rebound (two consecutive viral load >50 copies/ml) after initial suppression over 5 years of follow-up. Recovery of CD4 cell count was evaluated 6 and 12 months after EFV initiation. Analyses were stratified by weight (kg) group (I - <55; II - >55, <80 (reference); III - >80, <85; IV - >85, <90; V - >90, <95; VI - >95). RESULTS: The study included 19,968 patients, of whom 9.1, 68.3, 9.1, 5.8, 3.5, and 4.3% were in weight groups I-VI, respectively. Overall, 81.1% patients attained virological suppression, of whom 34.1% subsequently experienced viral load rebound. After multiple adjustments, no statistical difference was observed in time to undetectable viral load and virological rebound for heavier individuals compared to their normal-weight counterparts. Although heaviest individuals had significantly higher CD4 cell count at baseline, CD4 cell recovery at 6 and 12 months after EFV initiation was comparable to normal-weight individuals. CONCLUSION: Virological and immunological responses to initial EFV-containing regimens were not impaired in heavy individuals, suggesting that the standard 600 mg EFV dosage is appropriate across a wide weight range.
Keywords
Adult, Alkynes, Antiretroviral Therapy, Highly Active, Benzoxazines/*administration & dosage/*therapeutic use, *Body Weight, CD4 Lymphocyte Count, Cohort Studies, Cyclopropanes, Female, HIV Infections/*drug therapy, Humans, Male, Middle Aged, Obesity, Regression Analysis, Reverse Transcriptase Inhibitors/*therapeutic use, Treatment Outcome, Viral Load
Pubmed
Create date
25/08/2023 6:17
Last modification date
27/08/2023 7:01